Clik here to view.
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated...
TOKYO & BASKING RIDGE, N.J. The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)-based...
View ArticleClik here to view.
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
SAN ANTONIO bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung...
View ArticleClik here to view.
PopVax Announces 1.15 Million USD in Funding from the Bill ＆ Melinda Gates...
MUMBAI, India & HYDERABAD, India PopVax, an Indian full-stack biotechnology company developing novel mRNA vaccines and therapeutics using computational protein design, is pleased to announce...
View ArticleClik here to view.
ATLATL Hong Kong Innovation Center Officially Opens, Providing One-Stop...
HONG KONG ATLATL Hong Kong Innovation Center (ATLATL Hong Kong), a new state-of-the-art research facility designed to provide immediate, move-in-ready laboratory space for life science and biotech...
View ArticleClik here to view.
世界卒中组织成立全球联盟以推动脑卒中护理政策行动
日内瓦 (美国商业资讯)– 在10月29日“世界卒中日”之际，世界卒中组织（WSO）宣布成立全球联盟，在当下卒中已成为全球第二大死因和第三大致残原因的背景下，加快针对卒中的政策行动。 在过去的三十年里，全球的卒中负担增加了一倍。 预计到2050年，卒中的影响将增加三分之一。 这一增长可能导致每年970万人死亡，与卒中相关的残疾患者人数也将大幅增加。...
View ArticleClik here to view.
世界脳卒中機構、脳卒中ケアに関する施策を推進するためにグローバル連合を立ち上げ
ジュネーブ （ビジネスワイヤ） — 世界脳卒中デーである10月29日、世界脳卒中機構（WSO）は、現在、世界で死因の第2位、障害の原因の第3位となっている脳卒中に関する施策の推進を目的とした、グローバル連合の立ち上げを発表しました。...
View ArticleClik here to view.
Tempus Announces Collaboration With JW Pharmaceutical to Apply Real-World...
CHICAGO Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with JW Pharmaceutical, one of the most established pharmaceutical companies in Korea, to...
View ArticleClik here to view.
ADx NeuroSciences与Alamar Biosciences宣布合作，提供v解决方案，加速生物制药临床开发
比利时根特与加州弗里蒙特 (美国商业资讯)– ADx NeuroSciences是Fujirebio的全资子公司，也是神经退行性疾病生物标志物开发的领先企业，而Alamar Biosciences则在超灵敏免疫分析技术领域处于领先地位。今天，双方宣布合作，利用Alamar的NULISA™（核酸链接免疫分析法）免疫分析平台和ARGO™...
View ArticleClik here to view.
LabGenomics USA Completes Acquisition of IMD CLIA Labs
ROCKVILLE, Md. LabGenomics USA has successfully acquired Integrated Molecular Diagnostics (IMD) CLIA labs, bringing the total number of its CLIA-certified labs in the U.S. to four. This acquisition...
View ArticleClik here to view.
Dr. Reddy’s Named by Science Magazine in Top 20 Global Pharma Employers List...
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Survey conducted by Science. This marks...
View ArticleClik here to view.
Galderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific...
SINGAPORE Galderma (SWX:GALD), the pure-play dermatology category leader, today announced a new edition of the Galderma Aesthetic Injector Network (GAIN) event in the Asia-Pacific region, which...
View ArticleClik here to view.
JCR Pharmaceuticals Presents Preclinical Gene Therapy Research at the...
HYOGO, Japan JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that the Company presented preclinical data from its novel adeno-associated virus...
View ArticleClik here to view.
Advanced Energy推出全球首款采用对流散热设计的即用型CF类标准电源
科罗拉多州丹佛市 (美国商业资讯)– Advanced Energy（纳斯达克：AEIS）– 高度工程化的精密电源转换、测量和控制解决方案的全球领导者 – 已宣布推出NCF150系列高隔离、低漏电流型交流转直流电源，它的问世意味着医疗设备设计人员可以采用即用型产品满足IEC 60601-1医疗安全标准中的心脏起搏(CF)要求。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Advanced Energyが世界初の民生用CF定格対流冷却電源を発表
コロラド州デンバー （ビジネスワイヤ） — 高度な技術を駆使した高精度な電力変換、測定、制御ソリューションの世界的企業、Advanced Energy (Nasdaq: AEIS)は、高絶縁性かつ低漏洩電流のAC-DC電源、NCF150シリーズを発表しました。設計者は、民生製品を使用してIEC 60601-1医療安全規格の心臓フローティング（CF）要求を満たすことが可能になります。...
View ArticleClik here to view.
Asahi Kasei Medical launches Planova™ FG1 next-generation virus removal filter
TOKYO & NEW YORK & DÜSSELDORF Asahi Kasei Medical has launched the Planova™ FG1, a next-generation virus removal filter featuring higher flux for the manufacture of biotherapeutics, in...
View ArticleClik here to view.
Otsuka Announces Positive Interim Results from the Phase 3 Trial of...
PRINCETON, N.J. & TOKYO Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka), today announce positive topline interim data from the...
View ArticleClik here to view.
Catawba Research Announces Strategic Partnership With PharmaLegacy Laboratories
CHARLOTTE, N.C. Catawba Research, a leading global full-service Clinical Research Organization (CRO), is proud to announce a strategic partnership with PharmaLegacy Laboratories, a recognized leader...
View ArticleClik here to view.
CopilotIQ and Biofourmis Merge to Create the First End-to-End Platform for...
NASHVILLE, Tenn. & BOSTON CopilotIQ, the health tech company helping older Americans with chronic conditions live longer and healthier lives, and Biofourmis, a global technology-enabled care...
View ArticleClik here to view.
CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to Stelara®
SEOUL, South Korea Dong-A ST (President/CEO Jae-Hun Jung, KRX:170900) announced on October 18th that its biosimilar IMULDOSA® (active ingredient: ustekinumab, development code DMB-3115), referencing...
View ArticleClik here to view.
Celltrion公布皮下注射英夫利西单抗（CT-P13 SC）的两年事后分析结果，强调剂量递增是控制炎症性肠病继发性失应答的可选方案
韩国仁川 (美国商业资讯)– Celltrion今天在维也纳举行的“2024年欧洲联合胃肠病学（UEG）周”（United European Gastroenterology (UEG) Week 2024）上宣布了皮下注射英夫利西单抗（CT-P13 SC）剂量递增疗法的两年结果。...
View Article
